EcoDrugPlus

Endothelin Receptor Type B

Ensembl ID : ENSPREG00000002120
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSPREG00000002079
Gene Symbol: EDNRB
3 Cross references
195 Possible Orthologues:

Endothelin-1 Receptor-Like

Ensembl ID : ENSPREG00000002978
Gene Symbol: LOC103480879
4 Cross references
197 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSPREG00000010720
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSPREG00000010373
Gene Symbol: EGFR
4 Cross references
215 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSPREG00000017074
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSPREG00000014863
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSPREG00000008631
Gene Symbol: LOC103476687
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSPREG00000023046
Gene Symbol: ERBB2
1 Cross references
199 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSPREG00000012554
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPREG00000012150
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPREG00000016755
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).